Traws Pharma
TRAW
19 hedge funds and large institutions have $10.2M invested in Traws Pharma in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
170% more capital invested
Capital invested by funds: $3.8M → $10.2M (+$6.45M)
58% more funds holding
Funds holding: 12 → 19 (+7)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
3.31% more ownership
Funds ownership: 35.32% → 38.63% (+3.3%)
53% less call options, than puts
Call options by funds: $178K | Put options by funds: $376K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$914K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$650K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$548K |
| 4 |
VPC
Vestal Point Capital
New York
|
+$417K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$75.6K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$11.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.23K |
| 4 |
DB
Danske Bank
Copenhagen K,
Denmark
|
-$41 |
TRAW Hedge Fund Activity: Q4 2024 in Review
19 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2024, worth a combined $10.2M — up 170% from $3.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TRAW positions and 2 closed out — a net gain of 7 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $914K. The largest seller was Vanguard Group, cutting an estimated $75.6K.
- 19 institutional investors held Traws Pharma (TRAW) as of Q4 2024, up from 12 in Q3 2024.
- Funds reported $10.2M of Traws Pharma stock for Q4 2024, up 170% quarter-over-quarter.
- 9 funds opened new Traws Pharma positions in Q4 2024 and 2 closed out, a net change of +7 holders.
- The largest Traws Pharma buyer in Q4 2024 was Perceptive Advisors, an estimated $914K added.
- The largest Traws Pharma seller in Q4 2024 was Vanguard Group, an estimated $75.6K sold.
Based on aggregated 13F filings for Q4 2024.